计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| L288873-5mg |
5mg |
现货 ![]() |
| |
| L288873-10mg |
10mg |
现货 ![]() |
| |
| L288873-25mg |
25mg |
现货 ![]() |
| |
| L288873-50mg |
50mg |
现货 ![]() |
| |
| L288873-100mg |
100mg |
现货 ![]() |
|
| 别名 | 1-[4-[6-甲基-5-(3,4,5-三甲氧基苯基)-3-吡啶基]苯基]哌嗪 |
|---|---|
| 英文别名 | LDN-214117 | 1-(4-(6-methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine |
| 规格或纯度 | Moligand™, ≥98%(HPLC) |
| 英文名称 | LDN 214117 |
| 生化机理 | I型骨形态发生蛋白(BMP)受体ALK2的有效和选择性抑制剂(IC50 = 24 nM)。与TGF-β1相比,ALK1和ALK2的选择性优于ALK3,对BMP6抑制的选择性(IC50 = 100 nM)为164倍。与K 02288相比,具有更高的激酶组选择性和低细胞毒性。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 激活素 A 受体 1 型抑制剂;激活素 A 受体 IL 型抑制剂;骨形态发生蛋白受体 IA 型抑制剂;转化生长因子 beta 受体 1 抑制剂 |
| 产品介绍 |
LDN-214117是ALK2高效选择性抑制剂,IC50值为22nM,也能抑制BMP6,IC50值为100nM,对ALK5抑制力弱100倍。 |
| 纯度 | ≥98%(HPLC) |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504772656 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 1-[4-[6-methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]phenyl]piperazine |
| INCHI | 1S/C25H29N3O3/c1-17-22(19-14-23(29-2)25(31-4)24(15-19)30-3)13-20(16-27-17)18-5-7-21(8-6-18)28-11-9-26-10-12-28/h5-8,13-16,26H,9-12H2,1-4H3 |
| InChi Key | BHUXVRVMMYAXKN-UHFFFAOYSA-N |
| Smiles | CC1=C(C=C(C=N1)C2=CC=C(C=C2)N3CCNCC3)C4=CC(=C(C(=C4)OC)OC)OC |
| Isomeric SMILES | CC1=C(C=C(C=N1)C2=CC=C(C=C2)N3CCNCC3)C4=CC(=C(C(=C4)OC)OC)OC |
| 分子量 | 419.52 |
| Reaxy-Rn | 27525509 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=27525509&ln= |
| 溶解性 | 溶于DMSO, 最高浓度 (mg/mL): 41.95, 最高浓度(mM): 100;溶于ethanol, 最高浓度 (mg/mL): 41.95, 最高浓度(mM): 100 |
|---|---|
| 分子量 | 419.500 g/mol |
| XLogP3 | 3.900 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 6 |
| 精确质量Exact Mass | 419.221 Da |
| 单同位素质量Monoisotopic Mass | 419.221 Da |
| 拓扑极表面积Topological Polar Surface Area | 55.900 Ų |
| 重原子数Heavy Atom Count | 31 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 522.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H335: 可能引起呼吸道刺激 |
| 预防措施声明 |
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 |
| 1. Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M et al.. (2006) A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.. Nat Genet, 38 (5): (525-7). [PMID:16642017] |
| 2. Kaplan FS, Xu M, Seemann P, Connor JM, Glaser DL, Carroll L, Delai P, Fastnacht-Urban E, Forman SJ, Gillessen-Kaesbach G et al.. (2009) Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.. Hum Mutat, 30 (3): (379-90). [PMID:19085907] |
| 3. Pignolo RJ, Shore EM, Kaplan FS. (2011) Fibrodysplasia ossificans progressiva: clinical and genetic aspects.. Orphanet J Rare Dis, 6 (80). [PMID:22133093] |
| 4. Nakahara Y, Katagiri T, Ogata N, Haga N. (2014) ACVR1 (587T>C) mutation in a variant form of fibrodysplasia ossificans progressiva: second report.. Am J Med Genet A, 164A (1): (220-4). [PMID:24259422] |
| 5. Mohedas AH, Wang Y, Sanvitale CE, Canning P, Choi S, Xing X, Bullock AN, Cuny GD, Yu PB. (2014) Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.. J Med Chem, 57 (19): (7900-15). [PMID:25101911] |